Sunesis to Present at Upcoming Investor Conferences
Get Alerts SNSS Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences;
- Leerink Global Healthcare Conference Thursday, February 13th at 11:10 AM Eastern Time The Waldorf Astoria, New York City
- 2014 RBC Capital Markets' Global Healthcare Conference Tuesday, February 25th at 1:35 PM Eastern Time The New York Palace Hotel, New York City
A live webcast of the presentations will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
For additional information on Sunesis, please visit http://www.sunesis.com.
CONTACT: Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Eliza Schleifstein
Argot Partners
917-763-8106
[email protected]
Source: Sunesis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Resumes BorgWarner (BWA) at Outperform
- Sentric Specialty and Neumann Advisory Services Announce Strategic Partnership for Product Safety Risk Management
- 12 Top 1000x Meme Coins on the Radar: Apeing’s Upcoming Presale Countdown Hits the Final 8 Days
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share